Provided by Tiger Fintech (Singapore) Pte. Ltd.

Femasys Inc

1.19
-0.0550-4.44%
Volume:78.58K
Turnover:93.97K
Market Cap:32.17M
PE:-1.40
High:1.23
Open:1.19
Low:1.17
Close:1.24
Loading ...

Femasys Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Mar

BRIEF-Femasys Inc. FY EPS USD -0.85

Reuters
·
27 Mar

Femasys FY 2024 GAAP EPS $(0.85) Misses $(0.80) Estimate, Sales $1.629M Miss $2.684M Estimate

Benzinga
·
27 Mar

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

THOMSON REUTERS
·
27 Mar

Femasys Inc. FY EPS USD -0.85

THOMSON REUTERS
·
27 Mar

Press Release: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Dow Jones
·
27 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Femasys Inc : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
20 Mar

Femasys Inc. : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
19 Mar

Femasys enters partnership with CNY Fertility

TIPRANKS
·
19 Mar

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

GlobeNewswire
·
18 Mar

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

GlobeNewswire
·
13 Mar

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation

TIPRANKS
·
26 Feb

Femasys announces publication of ‘positive’ results from FemBloc trials

TIPRANKS
·
25 Feb

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results From Fembloc® Permanent Birth Control Clinical Trials

THOMSON REUTERS
·
25 Feb

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

GlobeNewswire
·
25 Feb